Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-03-03

FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CEREBYX (FOSPHENYTOIN SODIUM)

Snippet

SUPPL AP for CEREBYX (FOSPHENYTOIN SODIUM)